Using analytics and bioassays to de-risk your mRNA LNP drug development programme
Pharmaceutical Technology
FEBRUARY 15, 2023
Some of the variables include the chemical composition of the LNP, the manufacturing process and of course the RNA itself, whose design and production must elicit the intended therapeutic outcome.” They can’t be derived from animal products, but they are often synthesised in low purity – 60%-70% pure. weight abundance.
130 
Let's personalize your content